Feng Guo - Sihuan Pharmaceutical Executive Director
| SHPHFDelisted Stock | USD 0.1 0.00 0.00% |
Director
Dr. Guo Feng is Executive Director of the Company. He brought to the Group nearly 20 years of experiences in innovative drug RD and management especially in oncology drug RD strategy making, clinical development, registration, etc.. In 2000, Dr. Guo obtained his PhD degree in Clinical Pharmacology from the University of Toronto in Canada. In 2001, Dr. Guo joined Pfizer Inc. as associate director at Pfizer Global RD Headquarter based in Connecticut, US. In 2009, he was the Head of Clinical Pharmacology Asia of Pfizer in China. Since 2011, he was the Head of the Pfizer Wuhan RD center which he played a key role in building. During his time in Pfizer, Dr. Guo participated in the global development of multiple innovative drugs. In 2013, Dr. Guo joined Merck Co., Inc. as Vice President of Global RD and Head of Merck Biopharma RD Hub, a member of Merck Healthcare Global Clinical Development Executive Leadership team. During his service in Merck, Dr. Guo led his team in clinical development and registration of oncology drugs, including immuneoncology drugs, in China and Asia. In addition, Dr. Guo is an external scientific advisor of the Center for Drug Evaluation of China Food and Drug Administration. since 2017.
| Age | 53 |
| Tenure | 7 years |
| Professional Marks | Ph.D |
| Phone | 852 3628 3911 |
| Web | https://www.sihuanpharm.com |
Sihuan Pharmaceutical Management Efficiency
Sihuan Pharmaceutical's management efficiency ratios could be used to measure how well Sihuan Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Sihuan Pharmaceutical Holdings has accumulated 844.75 M in total debt with debt to equity ratio (D/E) of 0.14, which may suggest the company is not taking enough advantage from borrowing. Sihuan Pharmaceutical has a current ratio of 2.38, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Sihuan Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Sihuan Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sihuan Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sihuan to invest in growth at high rates of return. When we think about Sihuan Pharmaceutical's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 9 records | DIRECTOR Age | ||
| Adam Szweras | Aurora Cannabis | 48 | |
| Frank Fallwell | SNDL Inc | N/A | |
| Daniel JD | Phibro Animal Health | 52 | |
| Max Schwartz | OrganiGram Holdings | N/A | |
| Norma Beauchamp | Aurora Cannabis | 59 | |
| Jason Dyck | Aurora Cannabis | N/A | |
| David Lazzarato | Canopy Growth Corp | 64 | |
| Tyler Burns | Canopy Growth Corp | N/A | |
| Margaret Atkins | Aurora Cannabis | 63 | |
Management Performance
| Return On Equity | -0.0487 | |||
| Return On Asset | -4.0E-4 |
Sihuan Pharmaceutical Leadership Team
Elected by the shareholders, the Sihuan Pharmaceutical's board of directors comprises two types of representatives: Sihuan Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sihuan. The board's role is to monitor Sihuan Pharmaceutical's management team and ensure that shareholders' interests are well served. Sihuan Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sihuan Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Weicheng Guo, Deputy Chairman, CEO and Member of Nomination Committee | ||
| Xianhui Meng, Deputy General Manager of Sales and Marketing and Executive Director | ||
| Yanling Chen, Joint Director | ||
| Guili Miao, Chief CEO | ||
| Kin Li, Joint Sec | ||
| Fengsheng Che, Co-Founder, Executive Chairman and Member of Remuneration Committee | ||
| Jionglong Zhang, Non-Executive Director | ||
| Chengkon Shih, General Manager of Shandong Xuanzhu | ||
| Feng Guo, Executive Director |
Sihuan Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Sihuan Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0487 | |||
| Return On Asset | -4.0E-4 | |||
| Profit Margin | (0.05) % | |||
| Operating Margin | (0) % | |||
| Current Valuation | 506.36 M | |||
| Shares Outstanding | 9.33 B | |||
| Shares Owned By Insiders | 55.02 % | |||
| Shares Owned By Institutions | 4.21 % | |||
| Price To Earning | 8.75 X | |||
| Price To Book | 0.81 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Other Consideration for investing in Sihuan Pink Sheet
If you are still planning to invest in Sihuan Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sihuan Pharmaceutical's history and understand the potential risks before investing.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |